| 1 |
32566462 | Peripheral Artery Disease and Stroke. | 2020 Apr |
2 |
| 2 |
30756132 | Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus. | 2019 May |
1 |
| 3 |
30995112 | Functional effects of blocking VEGF/VEGFR2 signaling in the rat urinary bladder in acute and chronic CYP-induced cystitis. | 2019 Jul 1 |
2 |
| 4 |
31040105 | Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents. | 2019 Jul |
2 |
| 5 |
27562137 | The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin's lymphoma. | 2016 Oct |
2 |
| 6 |
24485462 | Sensitizing protective tumor microenvironments to antibody-mediated therapy. | 2014 Jan 30 |
1 |
| 7 |
23860526 | VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. | 2013 Aug 20 |
2 |
| 8 |
23979202 | Association between baseline VEGF/sVEGFR-2 and VEGF/TSP-1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer. | 2013 Apr-Jun |
1 |
| 9 |
16322118 | Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. | 2006 Feb |
2 |
| 10 |
16877730 | Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. | 2006 Aug 1 |
2 |
| 11 |
11863115 | Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. | 2002 Jan |
1 |